GREENSTONE LLC INTRODUCES PHENYTOIN TABLETS Generic of DILANTIN® INFATABS®

PEAPACK, N.J., December 2012 — Greenstone LLC, the U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Phenytoin Tablets, USP to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 50mg.

Greenstone’s Phenytoin Tablets, USP product is the authorized generic of, and equivalent to the innovator’s product, DILANTIN® (phenytoin, USP) INFATABS®. Their new authorized generic adds to Greenstone’s consistently growing line of products, and is backed by the power and scale of Pfizer’s 163-year worldwide reputation for a commitment to integrity, quality, and supply reliability. As a subsidiary of Pfizer, Greenstone operates under the same values and commitment to bring quality authorized generics to customers, payers, and the patients they serve.

See the Full Prescribing Information, for Greenstone’s Phenytoin Tablets, USP at http://www.greenstonellc.com/product-list.aspx. For more information about Greenstone LLC and its products, visit http://greenstonellc.com.

About Greenstone. Greenstone LLC, established in 1993, is a wholly owned subsidiary of Pfizer Inc, one of the largest pharmaceutical companies in the world. Greenstone, which focuses on customer service, markets a broad line of quality Authorized Generics—along with an expanding line of ANDA (Abbreviated New Drug Application) generics. Greenstone authorized generics, well known for having the same physical characteristics as the innovators' brands, are supported by state-of-the-art distribution and operations services. Greenstone is working with numerous brand pharmaceutical companies to assist in their "post-exclusivity" planning, with a focus on Authorized Generics. The company offers a robust product pipeline that highlights quality generic equivalents to some of the best-selling branded pharmaceuticals. Greenstone LLC will continue to offer numerous future product opportunities for pharmacies and its trade partners.

Download Catalog

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.